Sign in

Trial result ·

L-citrulline treatment of nitric oxide deficiency in MELAS a phase I dose-finding and safety study.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This was an early-stage trial of L-citrulline in adults with MELAS. MELAS is a mitochondrial disease that can cause stroke-like events. The team thinks low nitric oxide may cut blood flow in tiny vessels. They wanted to find the highest dose people could take safely. The 10 people got 10 g, 20 g, 30 g or 40 g. The team looked for harmful side effects and changes in brain blood flow. They also measured some substances in the blood.

What they found

No dose caused side effects bad enough to limit the dose. Still, some blood markers tied to arginine harm rose at 30 g and 40 g. Brain blood flow went up in some people. In 6 of these people, the dose was 40 g. The largest rise in flow was at the back of the brain. On 40 g, blood levels of arginine and citrulline rose a lot. This was seen at the end of treatment.

What it means for patients

The authors say no dose caused harm that set a limit. But some blood markers rose at 30 g and 40 g. This rise needs more study. They say a future study should check these markers many times. This would show if the higher doses are safe. It would also show if the rise lasts in the long run.

Why it is not certain yet

Only 10 people took part. Very few people got the lower doses. There was no placebo group to compare with. So this trial cannot show whether L-citrulline helps. The authors say a placebo-controlled trial is needed for that. It is not yet known if the marker rise lasts in the long run.

Source

L-citrulline treatment of nitric oxide deficiency in MELAS a phase I dose-finding and safety study.

PubMed · PMID 42520344

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Mitochondrial disease publications